ESTRO 2024 - Abstract Book

S923

Clinical - CNS

ESTRO 2024

2) from: https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/Interim_guidance_update_ following_closure_of_SIOP_CNS_GCT_II_April_2021_Final.pdf 3) Fonseca A, Cécile Faure ‐ Conter, Murray MJ, Fangusaro J, Bailey S, Goldman S, et al. Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. Neuro-oncology. 2022 Feb 26;24(11):1950 – 61. 4) Calaminus G, Didier Frappaz, Rolf ‐ Dieter Kortmann, Thankamma Ajithkumar, Pietsch T, Alexandre Vasiljevic, et al. GCT-48. OUTCOME OF CNS MALIGNANT NON-GERMINOMATOUS GERM CELL TUMORS (GCT) WITH AFP > 1000 ng/ml AT DIAGNOSIS TREATED ACCORDING TO SIOP CNS GCT 96. Neuro-oncology. 2020 Dec 1;22(Supplement_3):iii337 – 8. 5) Calaminus G, Bison B, Cécile Faure Conter, Didier Frappaz, Peyrl A, Gerber NU, et al. GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy – final of the SIOP CNS GCT II study. Neuro-oncology. 2022 Jun 1;24(Supplement_1):i56 – 6. River [Internet]. www.cclg.org.uk. [cited 2023 Oct 24]. Available

2564

Mini-Oral

Age is a Surrogate for IDH-Status but not an Independent Risk Factor in Diffuse Gliomas

Connor Jarrett Kinslow 1 , Ann Mercurio 1 , Prashanth Kumar 1 , Markus D Siegelin 2 , Emre Kocakavuk 3,4 , Guy M McKhann 5 , Michael B Sisti 5 , Jeffrey N Bruce 5 , Peter D Canoll 2 , Fabio M Iwamoto 6 , David P Horowitz 1 , Alfred I Neugut 7 , Lisa A Kachnic 1 , Paul D Brown 8 , Simon K Cheng 1 , Tony J. C. Wang 1 1 Columbia University, Radiation Oncology, New York, USA. 2 Columbia University, Pathology, New York, USA. 3 Yale, Neurosurgery, New Haven, USA. 4 University Hospital Essen, DHematology and Stem Cell Transplantation, Essen, Germany. 5 Columbia University, Neurosurgery, New York, USA. 6 Columbia University, Neurology, New York, USA. 7 Columbia University, Medicine, New York, USA. 8 Mayo Clinic, Radiation Oncology, Rochester, USA

Purpose/Objective:

Age greater than 40 years is considered a high-risk feature and potentially an indication for chemoradiotherapy for low-grade gliomas based on studies conducted in the pre-molecular era. Older age is associated with IDH-wildtype status and may not have independent prognostic value.

Material/Methods:

We aggregated grade II and III primary glioma data from 3 prospectively enrolled cohorts (MSK-IMPACT, EORTC, and Columbia University) for pooled analysis.1 The Kaplan-Meier method and Cox proportional hazards regressions were used to access the association of age >40 years with progression-free survival (PFS). Findings were validated in other publicly available datasets.